Plus Therapeutics, Inc.

NasdaqCM PSTV

Plus Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 6,860,768

Plus Therapeutics, Inc. Shares (Diluted, Weighted) is 6,860,768 for the Trailing 12 Months (TTM) ending September 30, 2024, a 166.57% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Plus Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 2,573,709, a 78.16% change year over year.
Plus Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 1,444,606, a 126.91% change year over year.
Plus Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 636,642, a 135.55% change year over year.
Plus Therapeutics, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2020 was 270,276, a 745.16% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: PSTV

Plus Therapeutics, Inc.

CEO	Dr. Marc H. Hedrick M.B.A., M.D.
IPO Date	July 11, 2001
Location	United States
Headquarters	4200 Marathon Boulevard
Employees	20
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Key trends

Past 5 years